Clinical Trial: Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07543536) titled 'Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer' on April 09.

Brief Summary: This study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: Advanced/Metastatic Breast Cancer HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer

Intervention: DRUG: Megestrol Acetate + Trastuzumab Deruxtecan

Megestrol Acetate 160mg orally, days 1-5, ...